Residential College | false |
Status | 已發表Published |
Salvia miltiorrhiza Bge. (Danshen) for Inflammatory Bowel Disease: Clinical Evidence and Network Pharmacology-Based Strategy for Developing Supplementary Medical Application | |
Zhang, Siyuan; Luo, Hua; Sun, Shiyi; Zhang, Yating; Ma, Jiaqi; Lin, Yuting; Yang, Lin; Tan, Dechao; Fu, Chaomei; Zhong, Zhangfeng; Wang, Yitao | |
2022-01-19 | |
Source Publication | Frontiers in Pharmacology |
ISSN | 1663-9812 |
Volume | 12Pages:741871 |
Abstract | Inflammatory bowel disease (IBD) is a non-specific colorectal disease caused by multifaceted triggers. Although conventional treatments are effective in the management of IBD, high cost and frequent side effects limit their applications and have turned sufferers toward alternative and complementary approaches. Salvia miltiorrhiza Bge (Danshen) is an herbal medicine that reportedly alleviates the symptoms of IBD. A large body of research, including clinical trials in which Danshen-based products or botanical compounds were used, has unmasked its multiple mechanisms of action, but no review has focused on its efficacy as a treatment for IBD. Here, we discussed triggers of IBD, collected relevant clinical trials and analyzed experimental reports, in which bioactive compounds of Danshen attenuated rodent colitis in the management of intestinal integrity, gut microflora, cell death, immune conditions, cytokines, and free radicals. A network pharmacology approach was applied to describe sophisticated mechanisms in a holistic view. The safety of Danshen was also discussed. This review of evidence will help to better understand the potential benefits of Danshen for IBD treatment and provide insights for the development of innovative applications of Danshen. |
Keyword | Clinical Trial Danshen Inflammatory Bowel Disease Network Pharmacology Salvia Miltiorrhiza Bge |
DOI | 10.3389/fphar.2021.741871 |
URL | View the original |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Pharmacology & Pharmacy |
WOS Subject | Pharmacology & Pharmacy |
WOS ID | WOS:000749435200001 |
Scopus ID | 2-s2.0-85123942146 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Institute of Chinese Medical Sciences |
Corresponding Author | Zhong, Zhangfeng; Wang, Yitao |
Recommended Citation GB/T 7714 | Zhang, Siyuan,Luo, Hua,Sun, Shiyi,et al. Salvia miltiorrhiza Bge. (Danshen) for Inflammatory Bowel Disease: Clinical Evidence and Network Pharmacology-Based Strategy for Developing Supplementary Medical Application[J]. Frontiers in Pharmacology, 2022, 12, 741871. |
APA | Zhang, Siyuan., Luo, Hua., Sun, Shiyi., Zhang, Yating., Ma, Jiaqi., Lin, Yuting., Yang, Lin., Tan, Dechao., Fu, Chaomei., Zhong, Zhangfeng., & Wang, Yitao (2022). Salvia miltiorrhiza Bge. (Danshen) for Inflammatory Bowel Disease: Clinical Evidence and Network Pharmacology-Based Strategy for Developing Supplementary Medical Application. Frontiers in Pharmacology, 12, 741871. |
MLA | Zhang, Siyuan,et al."Salvia miltiorrhiza Bge. (Danshen) for Inflammatory Bowel Disease: Clinical Evidence and Network Pharmacology-Based Strategy for Developing Supplementary Medical Application".Frontiers in Pharmacology 12(2022):741871. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment